Advertisement

Topics

BioDevelops Pharma GmbH Company Profile

09:08 EST 17th December 2018 | BioPortfolio

BioDevelops, an independent Austrian company, was initially founded back in 2002 and first concentrated on biomarker applications. Due to an opportunity to engage in the development of a clinical Phase II product with AOP Orphan Pharmaceuticals, the company changed its focus early in 2004 and entered the Cystic Fibrosis arena.Following successful turnaround, BioDevelops started its research operations a few months later at the Institute for Pharmacology in Vienna and focused on strategies for treatment of cystic fibrosis. In Sept. 2004, the Medical University of Vienna sold respective IP rights to BioDevelops. Consequently, the company filed a US-patent for an approach to enhance cell surface expression of proteins targeting Protein-Folding Diseases. The preliminary data - obtained with the A2A-receptor - were later supported with experimental findings on CFTR, the protein which is mutated in cystic fibrosis. The underlying research has been published recently (for full paper see T. Milojevic; for review see M. Toews). In addition to the IP transfer, the University granted to BioDevelops a right of first refusal for all IP related to the content of the original patent. Accordingly, BioDevelops also exerted its prerogative in sponsoring the July 2005 submission of a “second medical use” patent for proteasome inhibitors in the treatment of cystic fibrosis.

Location

c/o Institute for PharmacologyWaehringer Strasse 13A
Vienna
1090
Austria

Contact

Phone: 43.1.710.6616
Fax: 43.1.710.6614
Email: board@biodevelops.com


News Articles [655 Associated News Articles listed on BioPortfolio]

Heidelberg Pharma: GMP-Produktion von Krebswirkstoff etabliert

Frankfurt am Main (www.aktiencheck.de) - Heidelberg Pharma-Aktienanalyse von Analyst Thomas J. Schießle von der EQUI.TS GmbH: Thomas J. Schießle, Analyst der EQUI.TS GmbH, rät in einer aktuellen Ak...

Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350

Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and ...

Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 26062018] Prices from USD $350

Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and ...

New financing round at oncgnostics GmbH close

The life sciences company oncgnostics GmbH was able to double its investment of 750,000 euros following the very rapid and successful completion of its second crowd investing campaign on Seedmatch. A...

DGAP-Adhoc: CO.DON AG: CO.DON AG zeichnet Term Sheet mit der Haemo Pharma GmbH über den Vertrieb von Spherox in Österreich (deutsch)

CO.DON AG: CO.DON AG zeichnet Term Sheet mit der Haemo Pharma GmbH über den Vertrieb von Spherox in Österreich DGAP-Ad-hoc: CO.DON AG / Schlagwort(e): Markteinführung CO.DON AG: CO.DON AG zeichnet....

Royalties under patent licence agreements: can they remain payable even if the licensed patents(s) are revoked or not practised? Lessons from Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH

Précis In its recent decision in Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH (7 July 2016), the Court of Justice of the EU (“CJEU”) has ruled that an obligati...

Pediapharm acquires rheumatology-focused Medac

Pediapharm Inc. acquired privately-held specialty pharmaceuticals company Medac Pharma Inc. (wholly owned subsidiary of German pharma medac GMBH) for total consideration of $50mm.

Laufende Fusionskontrollverfahren: Bruker Daltonik GmbH, Bremen (D); Erwerb einer Mehrheitsbeteiligung von 80% an der HAIN LIFESCIENCE GmbH, Nehren (D);

Datum der Anmeldung:28.08.2018Aktenzeichen:B3-128/18Unternehmen:Bruker Daltonik GmbH, Bremen (D); Erwerb einer Mehrheitsbeteiligung von 80% an der HAIN LIFESCIENCE GmbH, Nehren (D);Produktmärkte:in.....

PubMed Articles [34 Associated PubMed Articles listed on BioPortfolio]

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Clinical trials go virtual, big pharma dives in.

Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals.

Research on effectiveness of DAA is limited. Existing researches explore impact of DAA only on relationship between drug manufacturers and consumers. However, in reality, pharma marketing revolves aro...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.

According to the Treaty on the Eurasian Economic Union, a common pharmaceutical market was supposed to become operational on January 1, 2016. Nevertheless, the responsible parties did not meet the dea...

Clinical Trials [124 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects

The purpose of this study is to confirm a significant influence of ezetimibe and sirolimus on each others pharmacokinetics

A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects

The purpose of this trial is to compare the pharmacokinetic characteristics of two isosorbide -5 -mononitrate extended -release tablets 40 mg of Qilu Pharmaceutical Co., Ltd and ISMO Retar...

Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF

"This is a randomised, double-blind, placebo-controlled multi-centre study to investigate safety and tolerability and to provide pharmacokinetic and pharmacodynamics information of orally ...

Companies [1280 Associated Companies listed on BioPortfolio]

BioDevelops Pharma GmbH

BioDevelops, an independent Austrian company, was initially founded back in 2002 and first concentrated on biomarker applications. Due to an opportunity to engage in the development of a clinical Phas...

Chemie-Kontor GmbH

Chemie-Kontor GmbH trades with chemical specialities for customers in Pharma-, Agro-, Cosmetics and Nutrition Industries and offers a broad range of services. Chemie-Kontor GmbH is agent for: Amberger...

INJEX Pharma AG

INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and INJEX Vertrieb Deutschland GmbH are specialized in the development, manufacturing and marketing in the m...

CROMA-PHARMA GmbH

CROMA-PHARMA is a family owned, internationally orientated pharmaceutical company, based in Korneuburg, Austria. CROMA-PHARMA´s areas of activity are orthopedics, ophthalmology...

Ratiopharm

On June 29, 2000, ratiopharm GmbH, Europe's largest generic drug company, purchased Technilab Pharma to establish ratiopharm's generic operations in Canada. Long before being acquired by ratiopharm Gm...

More Information about "BioDevelops Pharma GmbH" on BioPortfolio

We have published hundreds of BioDevelops Pharma GmbH news stories on BioPortfolio along with dozens of BioDevelops Pharma GmbH Clinical Trials and PubMed Articles about BioDevelops Pharma GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioDevelops Pharma GmbH Companies in our database. You can also find out about relevant BioDevelops Pharma GmbH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cystic Fibrosis
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...


Corporate Database Quicklinks



Searches Linking to this Company Record